Doctors Health Press, a division of Lombardi Publishing Corporation and publisher of various natural health newsletters, books, and reports, including the popular online Doctors Health Press e-Bulletin, is reporting on a new study finding a new way to target previously untreatable breast cancer receptors.

Doctors Health Press, a division of Lombardi Publishing Corporation and publisher of various natural health newsletters, books, and reports, including the popular online Doctors Health Press e-Bulletin, is reporting on a new study finding a new way to target previously untreatable breast cancer receptors.

As the article “Breast Cancer Hope: New Way to Target Receptor Cells” reports, there are already cancer drugs that can block the HER2 receptors and limit their growth, but about one in five breast cancer tumors lacks the receptors and so the cancer drugs cannot specifically target these cancer-promoting receptors. Scientists call these types of cancers “triple-negative” because they’re so difficult to treat.

The Doctors Health Press e-Bulletin article states that since the cancer drugs that work on some people’s HER2 receptors don’t work on the people with triple-negative cancer, researchers have tried to find other ways to target them. They’ve discovered another receptor called EGFR that also promotes the growth of cancer cells, but so far, no drugs have been found that can block EGFR effectively.

But, as the article notes, that’s why researchers at the Weizmann Institute of Science in Israel are studying new drugs that can destroy EGFR, and thus stop the multiplying of cancer cells in these breast cancer patients. Their study, published in the Proceedings of the National Academy of Science, found a solution: treat triple-negative breast cancer with two EGFR blocking antibodies at the same time, instead of just one.

According to Doctors Health Press e-Bulletin, the researchers studied the effect on mice with triple-negative breast cancer and found that using two antibodies actually did prevent the spread of triple-negative tumors. The most revolutionary part of their research was that treating this molecule with two antibodies simultaneously worked much better than if they were to treat it with the same antibodies, one after the other. The combined weight of the two antibodies actually caused the EGFR molecule to collapse inwards and prevent its growth. Then, the cancer cells stopped receiving growth signals from the EGFR molecule.

As Doctors Health Press e-Bulletin concludes, this finding could have a dramatic impact on how breast cancer is treated—and may bring researchers closer to finding a cure.

(SOURCES: Ferraroa, D., et al., “Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR,” Proceedings of the National Academy of Sciences 2013; 1,815-1,820; “Two Antibodies Are Better Than One,” Weizmann Canada February 2013.)

Doctors Health Press e-Bulletin is a daily e-letter providing natural health news with a focus on natural healing through foods, herbs, and other breakthrough health alternative treatments. For more information on Doctors Health Press, visit http://www.doctorshealthpress.com.

Doctors Health Press believes in the healing properties of various alternative remedies, including Traditional Chinese Medicine. To see a video outlining the Doctors Health Press’ views on Traditional Chinese Medicine, visit http://www.doctorshealthpress.com/chinesemedicine.